Bormioli Pharma, an international leader in pharmaceutical packaging and medical devices, announced today the third edition of its Sustainability Report.

This edition outlines and consolidates the strong progress Bormioli Pharma has made in promoting sustainable growth in the communities where the Company live and work and highlights its strong commitment to supporting the pharmaceutical industry in its transition towards environmentally friendly solutions.

Of the main actions took by the Company during the year, the decision of proceeding with the external assurance of the Report two years ahead of legal obligations has been one of the most pioneering among the industry. In 2023, ESG team and Governance have been also reinforced, leading to the definition of robust processes contained in its ESG Policy. Moreover, the Group is already taking steps to prepare for the adoption of the new reporting system required by the EU Directive “Corporate Sustainability Reporting Directive” (CSRD).

In terms of the key sustainability targets, Bormioli Pharma confirmed to be committed in the 30

“In 2023 we have worked energetically to be an important driver of responsible growth, remarking our role as a partner of the pharmaceutical industry in developing increasingly widespread, effective and sustainable medical practices”, commented Andrea Lodetti, CEO of Bormioli Pharma. “Among the initiatives implemented during this path, we have further extended one of the widest sustainable packaging offering available in the pharma industry, EcoPositive, a concrete action to support the EU’s goals for sustainable packaging.”